It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Insufficiency of vitamin D levels often occur in individuals with schizophrenia and first-episode psychosis (FEP). However, it is unknown whether this represents a biological predisposition, or it is essentially driven by illness-related alterations in lifestyle habits. Lower vitamin D has also been associated with adverse neurodevelopmental outcomes and predominant negative psychotic symptoms. This study aimed to investigate the contribution of polygenic risk score for circulating 25-hydroxyvitamin D concentration (PRS-vitD) to symptom presentation among individuals with FEP enrolled in the Athens First-Episode Psychosis Research Study (AthensFEP n = 205) and the Psychosis Incident Cohort Outcome Study (PICOS n = 123). The severity of psychopathology was evaluated using the Positive and Negative Syndrome Scale at baseline and follow-up assessments (AthensFEP: 4-weeks follow-up, PICOS: 1-year follow-up). Premorbid intelligence and adjustment domains were also examined as proxy measures of neurodevelopmental deviations. An inverse association between PRS-vitD and severity of negative symptoms, in particular lack of social motivation, was detected in the AthensFEP at baseline (adjusted R2 = 0.04, p < 0.001) and follow-up (adjusted R2 = 0.03, p < 0.01). The above observation was independently validated in PICOS at follow-up (adjusted R2 = 0.06, p < 0.01). No evidence emerged for a relationship between PRS-vitD and premorbid measures of intelligence and adjustment, likely not supporting an impact of lower PRS-vitD on developmental trajectories related to psychotic illness. These findings suggest that polygenic vulnerability to reduced vitamin D impairs motivation and social interaction in individuals with FEP, thereby interventions that encourage outdoor activities and social engagement in this patient group might attenuate enduring negative symptoms.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 National and Kapodistrian University of Athens, Eginition University Hospital, Department of Psychiatry, Medical School, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800); Theodore-Theohari Cozzika Foundation, Neurobiology Research Institute, Athens, Greece (GRID:grid.5216.0)
2 University of Verona, Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement Sciences, Verona, Italy (GRID:grid.5611.3) (ISNI:0000 0004 1763 1124)
3 National and Kapodistrian University of Athens, Eginition University Hospital, Department of Psychiatry, Medical School, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800)
4 King’s College London, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College, National Institute for Health Research, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
5 Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College, National Institute for Health Research, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); King’s College London, Department of Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)